Small Pharma Inc. (DMT.V)
| Previous Close | 0.1550 |
| Open | 0.1450 |
| Bid | 0.1550 x N/A |
| Ask | 0.1600 x N/A |
| Day's Range | 0.1450 - 0.1600 |
| 52 Week Range | 0.0600 - 0.2200 |
| Volume | |
| Avg. Volume | 350,681 |
| Market Cap | 51.45M |
| Beta (5Y Monthly) | 1.65 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.50 |
GlobeNewswireSmall Pharma Reports Positive Top-line Data from SPL026 (DMT)-SSRI Drug Interaction Study in Patients with Major Depressive Disorder
Efficacy Chart Efficacy results in both cohorts at baseline and at Week 4 following the dose of SPL026 with support therapy • Results suggest that SSRIs enhance the efficacy of SPL026 (DMT) when administered to MDD patients on a stable dose of SSRIs versus patients not on SSRIs • At Week 4, 100% of patients in the SSRI cohort responded to SPL026 (DMT) with 92% of patients in remission from depression • No apparent differences in the safety and tolerability profile of SPL026 (DMT) following admin
NewsfileCybin to Acquire Small Pharma Inc.
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics -- Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy -- Combined portfolio creates the industry's largest, most advanced, well-protected deuterated DMT program -- Combination creates the largest intellectual property portfolio in the psychedelic drug development sector with 28 patents granted and 158 patents pend
GlobeNewswireSmall Pharma Reports Fiscal First Quarter 2024 Highlights
• Last patient dosed in SPL026-SSRI drug interaction study with data readout anticipated in Q3 2023 • Potential for an expedited route to an international, multi-site Phase II study with SPL028 in 2024, based on clinical findings across SPL026 and SPL028 programs to date • SPL026 Phase IIa clinical trial results well-received at several international scientific conferences • Anticipated cash runway to at least Q4 2024 following recent operational restructuring LONDON, July 27, 2023 (GLOBE NEWSWI
